溶性曼诺酶受体:高氏病的潜在生物标志物
Brendan Beaton1,2,3, Derralynn A Hughes1,2
1Department of Haematology, Royal Free NHS Trust, London, UK.
European journal of haematology
|January 11, 2024
概括
溶性曼诺酶受体 (sMR) 水平在高氏病 (GD) 中升高,与疾病严重程度相关. 对GD的治疗显著降低了sMR,表明其作为生物标志物的潜力.
科学领域:
- 生物化学 生物化学
- 免疫学 免疫学 免疫学
- 罕见疾病 罕见疾病
背景情况:
- 溶性曼诺酶受体 (sMR) 与巨细胞活动有关,在炎症条件下升高.
- 氏病 (GD) 涉及巨细胞功能的改变,并利用曼诺酶受体进行酶替代疗法 (ERT).
研究的目的:
- 首次研究高氏病 (GD) 中可溶性曼诺酸受体 (sMR) 水平.
- 为了将sMR与临床表现和已确定的GD生物标志物相关联.
主要方法:
- 在未接受治疗的GD患者,治疗后的患者和健康对照中,sMR使用ELISA量化.
- sMR水平与临床参数 (器官体积,血液计数,骨髓负担,免疫球蛋白) 和GD生物标志物相关.
主要成果:
- 与治疗后患者和对照人群相比,未接受治疗的GD患者的sMR水平显著更高.
- sMR与脏和肝脏体积,骨髓负担,免疫球蛋白水平以及与血红蛋白和血小板计数的逆相关性有显著的相关性.
- sMR还与已确立的GD生物标志物有很强的相关性,包括奇托里奥西达酶,骨质活素,费里丁,PARC和CCL3.
结论:
- 溶性曼诺酶受体 (sMR) 是高氏病的潜在生物标志物.
- sMR水平与GD临床严重程度和已确定的生物标志物相关.
- 在GD的治疗干预导致sMR水平的显著降低.
相关概念视频
Oligosaccharide Assembly
2.9K
Protein glycosylation starts in the ER lumen and continues in the Golgi apparatus. Glycosyltransferases catalyze the addition of sugar molecules or glycosylation of proteins. Usually, these enzymes add sugars to the hydroxyl groups of selected serine or threonine residues to form O-linked glycans or the amino groups of asparagine residues to form N-linked glycans. Different positions on the same polypeptide chain can contain differently linked glycans.
Multiple sugar molecules that may or may...
Multiple sugar molecules that may or may...
2.9K
Glucose Transporters
22.8K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.8K


